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Summary 
Acidic mammalian chitinase (AMCase) is produced in the lung during 
allergic inflammation and asthma and inhibition of enzymatic activity 
has been considered as a therapeutic strategy. However, most chitinase 
inhibitors are non-selective, additionally inhibiting chitotriosidase 
activity. Here we describe bisdionin F, a competitive AMCase inhibitor 
with 20-fold selectivity for AMCase over chitotriosidase, designed by 
utilising the AMCase crystal structure and dicaffeine scaffold. In a 
murine model of allergic inflammation, bisdionin F-treatment attenuated 
chitinase activity and alleviated the primary features of allergic 
inflammation including eosinophilia. However, selective AMCase 
inhibition by bisdionin F also caused dramatic and unexpected 
neutrophilia in the lungs. This class of inhibitor will be a powerful tool to 
dissect the functions of mammalian chitinases in disease and represents 
a synthetically accessible scaffold to optimize inhibitory properties in 
terms of airway inflammation. 
 

 INTRODUCTION 
Chitin, the second most abundant polysaccharide in nature, is a principal 
component of the arthropod exoskeleton, nematode eggshell and fungal 
cell wall. Although mammals themselves do not synthesize chitin, they 
are continually exposed to this polymer through inhalation and exposure 
to chitin-containing pathogens. Chitin accumulation is limited through 
hydrolysis of (14) glycosidic bonds by chitinases, members of the 
evolutionary conserved glycoside hydrolase family 18 (GH18). Mammals 
have two genes encoding active chitinases, chitotriosidase (CHIT1) and 
acidic mammalian chitinase (AMCase), that represent an ancient gene 
duplication event and show sequence homology to bacterial 
chitinases(Bussink, et al. 2007). More recent gene duplications have 
yielded the homologous chitinase-like proteins (CLPs), with mutations 
within the enzymatic machinery rendering the catalytic site inactive 
(Zaheer ul, et al. 2007). Although the functions of both chitinases and 
CLPs in mammals are still poorly understood, it is becoming clear that 
their expression is regulated in both innate and adaptive immune 
responses. CHIT1, which is expressed exclusively in phagocytes (Boot, et 
al. 2005), is thought to play an important role in the mammalian innate 
immune response against fungi, bacteria and other pathogens (Barone, 
et al. 2003; Labadaridis, et al. 2005).  Conversely, increased production 
of AMCase and CLPs Ym1, Ym2, BRP-39 in rodents; and YKL-39 and YKL-
40 in humans, is a prominent feature of Th2-driven pathologies, 
including infection, allergic inflammation and asthma (reviewed in 
(Sutherland, et al. 2009).   
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AMCase was first described to be expressed in the gastrointestinal tract 
and lungs of rodents and humans (Boot, et al. 2001). AMCase is 
expressed in tissue macrophages and epithelial cells, with its production 
driven by Th2-cytokines IL-4 and IL-13 (Zhu, et al. 2004).  Early 
exploration of mammalian chitinase function implicated AMCase as a 
mediator of Th2-driven allergic airway diseases following the use of the 
chitinase inhibitor allosamidin, a pseudo-trisaccharide natural product 
derived from Streptomyces species (Sakuda 1986), in murine models 
(Zhu, et al. 2004).  Treatment of allergen-challenged mice with 
allosamidin or demethylallosamidin significantly reduced eosinophilia, a 
hallmark of allergic inflammation (Matsumoto, et al. 2009; Zhu, et al. 
2004). Although both compounds inhibit chitinase activity in vivo, only 
demethylallosamidin treatment reduces allergen or IL-13–induced airway 
hyper-responsiveness. Despite beneficial actions in models of Th2-driven 
allergic inflammation, the therapeutic potential of these compounds is 
limited due to their expensive and complex synthesis and commercial 
unavailability. In addition, allosamidin has a broad range of activity 
against all family 18 chitinases (Berecibar, et al. 1999), and possesses 
physicochemical properties that are not compatible with a drug-like 
compound, such as high molecular weight (604.7 Da), an undesirably low 
clogP (-4.7) and poor ligand efficiency (-0.25 kcalmol-1 atom-1 for fungal 
chitinase) (Vaaje-Kolstad, et al. 2004). Allosamidin is a more effective 
inhibitor of CHIT1 than AMCase (IC50 murine CHIT1 [mCHIT1] 50 nM and 
murine AMCase [mAMCase] 400 nM) (Zheng, et al. 2005) (Boot, et al. 
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2001). This is of particular concern as CHIT1 is not an effector molecule 
in allergic inflammation and is rather regarded as a host-defense 
mechanism against chitin-containing pathogens (reviewed in(Sutherland, 
et al. 2009). Thus, there is a need to identify compounds that are drug-
like, selective inhibitors of AMCase that can be used in animal models to 
dissect the roles of the chitinases in allergic airway inflammation, and 
potentially further develop as anti-asthma therapies. 
We recently identified xanthine derivatives as promising leads for GH18 
inhibitors (Rao, et al. 2005) and subsequently developed a low 
micromolar chitinase inhibitor composed of two linked caffeine 
molecules (bisdionin) with desirable drug-like properties, a 
crystallographically defined binding mode and excellent synthetic 
accessibility (Schuttelkopf, et al. 2006).  Here we describe the rational 
design of a novel AMCase inhibitor, bisdionin F, with 20-fold selectivity 
for AMCase over CHIT1 and demonstrate in vivo activity in a mouse 
model of acute allergic inflammation. Bisdionin F treatment in allergen-
challenged mice reduced eosinophil recruitment and measurements of 
ventilatory function. Unexpectedly however, treatment with bisdionin F 
also resulted in neutrophilia and changes to expression of genes 
associated with remodelling. These studies highlight the complex 
mechanistic pathways surrounding the therapeutic inhibition of AMCase 
activity. Nonetheless, the potent selective activity of bisdionin F in vitro 
and in vivo and its relatively easy synthesis, makes this inhibitor an 
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invaluable tool for the chemical biological dissection of the roles of the 
different mammalian chitinases. 
 

RESULTS 
Rational design of bisdionin F, a hAMCase selective inhibitor 
A recent report described the reduction of airway eosinophilia upon 
inhibition of total broncho-alveolar chitinase activity with the natural 
product chitinase inhibitor allosamidin (Zhu, et al. 2004).  We recently 
described the bisdionins, dixanthine derivatives that are micromolar 
inhibitors of family 18 chitinases (Schuttelkopf, et al. 2006). A high-
resolution crystal structure of bisdionin B (C2-dicaffeine) complexed 
with Aspergillus fumigatus chitinase B1 (AfChiB1) was solved and 
revealed the binding mode of bisdionin B (Schuttelkopf, et al. 2006).  
Whilst being less energetically favourable, the caffeine linker length of 
these molecules could be modified to alleviate strain and result in a 
more potent inhibitor (Schuttelkopf, et al. 2010). The most potent of 
these, bisdionin C (Fig. 1A), is a drug-like molecule as assessed by 
Lipinski’s rule of five: it has six hydrogen bond acceptors and no 
hydrogen bond donors, a molecular weight of 400.4 Da, a clogP of 
approximately 0 and a ligand efficiency of -0.41 kcalmol-1 atom-1 against 
AfChiB1 (Schuttelkopf, et al. 2010). We investigated whether bisdionin 
C would inhibit human AMCase (hAMCase) and/or human chitotriosidase 
(hCHIT1). Assesment of chitinase activity using a fluorescent substrate 
revealed that while bisdionin C inhibits hAMCase and hCHIT1 in the 
micromolar range, it does so with no apparent selectivity (Fig. 2). 
To facilitate structure-guided optimisation of the bisdionin scaffold into 
a potent, selective hAMCase inhibitor, the crystal structure of the 
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hAMCase-bisdionin C complex was determined to 2.2 Å resolution (Table 
I, Fig. 1B). The native structure of hAMCase has recently been reported 
(Olland, et al. 2009), giving an RMSD of 0.80 Å with the structure 
reported here. The loops on the AMCase TIM barrel (()8 fold) produce 
a deep active site cleft similar to other “bacterial-type” family 18 
chitinases. Bisdionin C spans the -1, -2 and -3 GlcNAc binding subsites of 
the AMCase chitooligosaccharide substrate (Fig. 1C). The methyl 
xanthine units bind at the bottom of the active site, stacking on the 
indole groups of Trp31 and Trp360 (Fig. 1C). The hydroxyl group of 
Tyr212 forms a hydrogen bond with N9, whereas the backbone N of 
Trp99 forms a hydrogen bond with O6. Water-mediated hydrogen bonds 
are formed between the carboxyl group of Asp213 and O2, and between 
the backbone oxygen and nitrogen atoms of Gly97 and Phe101, 
respectively, and bisdionin C O6’. 
Although hCHIT1 and hAMCase catalytic domains share 57% sequence 
identity, there are two amino acids near the catalytic machinery that 
are different in hAMCase, His269 (Arg269 in hCHIT1) and Ile300 (Met300 
in hCHIT1) (Fig. 1C). Interestingly, the N7 methyl group of bisdionin C 
appears to impose an unfavourable conformation of Asp138, a key 
catalytic residue that hydrogen bonds the catalytic acid 
(Glu140)/substrate N-acetyl group and stabilises the oxazolinium ion 
reaction intermediate during catalysis (Brameld, et al. 1998; Terwisscha 
van Scheltinga, et al. 1995; van Aalten, et al. 2001) (Fig. 1).  Given the 
unfavourable interactions of the N7 methyl group and the non-conserved 
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amino acid substitutions on the opposite side of the xanthine moiety, we 
explored the effects of the N7 methyl group on potency and selectivity. 
We synthesised bisdionin F, the N7-demethylated derivative of bisdionin 
C (Fig. 1A). A 2.25 Å crystal structure of the hAMCase-bisdionin F 
complex reveal that Asp138 now adopts the "up" conformation, 
generating an additional hydrogen bond with the N7 of the xanthine in 
the -1 subsite, and also interacting with the catalytic acid (Glu140). The 
inhibitor bisdionin F was shown to further increase hAMCase inhibition by 
over one order of magnitude compared to bisdionin C, competitively 
inhibiting the enzyme with a Ki = 420 ± 10 nM (Fig. 1B). The inhibitor 
shows this improved inhibition only towards hAMCase, not hCHIT1 (IC50 = 
17 μM), thus introducing 20-fold selectivity (Fig 2A). It should be noted 
that hAMCase possesses a more negatively charged active site, generated 
by the Arg269 (hCHIT1) to His269 (hAMCase) substitution, also lowering 
of the pH optimum of the enzyme. Thus, electrostatic effects may 
explain why the imidazole moiety, generated by removing the methyl 
group, is better accommodated by the hAMCase enzyme. 
Bisdionin F reduces chitinase activity in a murine model of allergic 
inflammation. 
To verify that, as expected, bisdionin F would have similar activity 
against the mouse enzyme, recombinant mAMCase was stably expressed 
in COS-7 cells. After 10 min incubation, bisdionin F treatment resulted 
in a concentration- dependent inhibition of mAMCase activity with an 
IC50 of 2.2 ± 0.2 μM (Fig. 2B). To test the in vivo efficacy of bisdionin F, 
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a well-established model of airway lung inflammation was used, in which 
mice are first sensitized with ovalbumin (OVA) i.p. and then challenged 
in the airways, leading to increased chitinase activity in the lung tissue 
(Zhu, et al. 2004). Enzymatic activity in lung homogenates of mice 
treated with 5 mg/kg bisdionin F (Fig. 3A) was assessed in this model. 
As previously reported, chitinase activity significantly increases upon 
allergic challenge, as assayed approximately 24 hr after the last 
challenge while treatment with bisdionin F significantly reduced 
chitinase activity in the lungs of both control PBS and OVA-challenged 
mice. 
Bisdionin F modulates allergen-induced inflammation 
To assess the impact of AMCase inhibition on allergen-induced 
inflammation, cellular infiltrate into the bronchoalveolar lavage fluid 
(BALF) was examined on cytospins from vehicle and bisdionin F -treated 
animals (Fig. 3B and 3C). As expected, acute OVA-challenge induced a 
significant increase in eosinophils, lymphocytes and macrophages in the 
lavage fluid compared to PBS-challenged mice. Strikingly, bisdionin F-
treated allergic mice were found to have significantly reduced total cell 
airway infiltrates (Fig. 3B, P < 0.01 compared to vehicle treatment), 
whereas cell numbers in PBS-challenged animals were not altered with 
chitinase inhibition. Differential counts of cells recovered from the BALF 
revealed a reduction in the number of lymphocytes and eosinophils 
following chitinase inhibition (Fig. 3C). However, the most 
unanticipated result of bisdionin F treatment was a 4-fold increase in 
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 neutrophil cell number compared to vehicle-treated OVA-challenged 
mice (Fig. 3C). 
Changes to inflammatory infiltrates were examined in haematoxylin and 
eosin stained lung sections (Fig. 3D and 3E). PBS-challenged mice had 
similar lung structure and cellular composition, whether treated with 
bisdionin F or vehicle (Fig. 3D, i and ii). Allergen challenge resulted in 
inflammatory cell influx into the lamina propria, perivascular and 
peribronchiolar regions of the lung. Following treatment with bisdionin F 
in allergic animals, inflammatory influx into the lung tissue was more 
striking (Fig. 3D and 3E). Staining with naphthol AS-D choloracetate 
esterase, a stain specific for neutrophil granulocytes, revealed 
predominant neutrophil influx in bisdionin F OVA-challenged mice (Fig. 
3F), consistent with the analysis of the BALF (Fig 3C). 
To investigate the cause of the bisdionin F-induced neutrophilic 
response, cytokine and chemokine secretion from OVA-specific tLN cell 
cultures were examined with Luminex multiplex bead array. Potent 
neutrophil chemotactic factors KC (murine IL-8 equivalent) and IL-17 
were not significantly altered in tLN cultures from chitinase inhibitor 
treated allergic mice (data not shown). However, both the secretion 
and expression of chemokine macrophage inhibitory protein-1 alpha 
(MIP-1), also a neutrophil chemoattractant, were enhanced by bisdionin 
F treatment in OVA-challenged animals (Fig. 3G and 3H). MIP-1 levels 
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were not altered by OVA-challenge alone, correlating with a lack of 
significant neutrophil recruitment in these mice (Fig. 3C). 
Altered eosinophil recruitment following bisdionin F treatment is 
dose-dependent 
At a dose of 5 mg/kg, bisdionin F decreased eosinophil cell number and 
increased neutrophil cell number resulting in an unfavourable cell 
recruitment profile for the treatment of allergy. Thus, we investigated 
whether a lower dose of bisdionin F would allow effects on neutrophil 
and eosinophil cell numbers to be segregated. 1 mg/kg was the lowest 
dose at which we could observe any chitinase inhibition and thus allergic 
animals were treated with 1 and 5 mg/kg of bisdionin F and eosinophil 
and neutrophil recruitment was assessed (Fig. 4A). Increases in 
eosinophilia of OVA-challenged mice were reduced by treatment with 
both 1 and 5 mg/kg dose. However, at both doses, bisdionin F 
treatment also resulted in a significant 2-4-fold increase in neutrophil 
cell number. A bronchoconstrictor, methacholine, was administered 
following challenge with OVA or PBS, and penH (enhanced pause), a 
measurement that reflects changes to ventillatory function in 
spontaneously breathing mice, as described in detail in the experimental 
procedures. As expected penH was significantly increased in vehicle-
treated allergic animals compared to naïve animals (P<0.001, Fig. 4C). A 
dose of 5 mg/kg bisdionin F had no effect on penH measurements in PBS-
challenged animals (results not shown). However, bisdionin F treatment 
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significantly reduced penH in allergic mice at both 1 and 5 mg/kg at the 
highest concentration of methacholine used. 
Expression of genes associated with tissue remodelling are altered 
by chitinase inhibition 
It has been suggested that chitinases play a role in tissue remodelling 
responses in models of infection and Th2-driven inflammation (reviewed 
in (Lee 2009) with eosinophils also implicated in remodelling. We thus 
predicted that chitinase inhibition, leading to reduced eosinophilia, 
might have beneficial effects on the expression of genes associated with 
lung remodelling. Contrary to our expectation, the expression of genes 
associated with remodelling including procollagen I, matrix-
metalloprotease-12 (MMP-12), and Ym1 (chitinase-like protein) were 
significantly increased in bisdionin F treated animals, while the tissue 
inhibitor of metalloproteinases 1 (TIMP-1) was down-regulated (Fig. 5A-
D). Furthermore, the ratio of MMP:TIMP expression was enhanced 2.5 
fold following bisdionin F treatment, suggesting enhanced MMP activity is 
likely (Fig. 5E). 
  

DISCUSSION 
The therapeutic targeting of chitinase enzymatic activity was proposed 
when it was discovered that AMCase is highly expressed in both animal 
models of allergic inflammation and in human asthmatics (Bierbaum, et 
al. 2005; Zhu, et al. 2004) and that non-specific inhibition of chitinases 
had anti-inflammatory effects (Matsumoto, et al. 2009; Zhu, et al. 
2004). However, the inhibitors used in these studies are not specific for 
AMCase and do not provide tangible starting points for the development 
of such compounds. With the aid of hAMCase structural data, we 
undertook the design of a selective hAMCase inhibitor that would allow 
us to more precisely dissect the role of AMCase in allergic inflammation. 
The design strategy for the novel chitinase inhibitor bisdionin F 
demonstrates that selective inhibitors of AMCase activity can be 
synthesised and as shown here, used in vivo to examine the function of 
AMCase during Th2-driven allergic inflammation. Importantly, our 
findings suggest that key properties of AMCase may have been 
overlooked using broad chitinase inhibitors. 
Bisdionin F showed micromolar affinity against recombinant mAMCase in 
vitro and reduced both the increased lung chitinase enzymatic activity 
induced by allergic OVA challenge and the basal level of chitinase 
activity in naïve mice. Treatment with bisdionin F significantly reduced 
eosinophil cell numbers in the lavage of allergic mice, an effect that has 
been previously described for other chitinase inhibitors (Matsumoto, et 
al. 2009; Zhu, et al. 2004). Although the central role of eosinophils in 
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the allergic reaction is sometimes debated, reduced eosinophil numbers 
are associated with improvements in ventilatory function and tissue 
remodelling (Flood-Page, et al. 2003; Humbles, et al. 2004).  In this 
current study, chitinase inhibition decreased penH in allergic animals at 
doses in which eosinophil recruitment was reduced by approximately 
50%, supporting the notion that eosinophils regulate ventilatory function.  
The most striking and consistent feature of bisdionin F treatment was 
the neutrophil recruitment observed in OVA-challenged mice but not 
control PBS-challenged mice. Whilst not considered a classical 
inflammatory mediator in Th2-driven allergy, neutrophils have 
increasingly and controversially been placed in the spotlight as 
important mediators of persistent and corticosteroid-resistant asthma 
(Green, et al. 2002; Jatakanon, et al. 1999).  Recent studies have 
correlated chronic asthma severity with the numbers of neutrophils in 
the sputum and bronchial biopsies (Louis, et al. 2000; Woodruff, et al. 
2001), with neutrophil recruitment and activation mediated largely by 
IL-8 (Monteseirin 2009). Bisdionin F-induced neutrophilia was 
accompanied by an increase in MIP-1 secretion and expression, both at 
the site of inflammation and the draining lymph nodes. Although the 
role of MIP-1 during allergic asthma has been described to a lesser 
extent than IL-8, the levels of MIP-1 are increased in lavage fluid from 
allergic asthmatics (Alam, et al. 1996) and hence may be an important 
component for induction of neutrophil chemotaxis. In addition to 
increased neutrophil numbers following bisdionin F treatment, we 
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observed alterations in airway remodelling genes that would be 
predicted to have negative consequences for lung function. Whether 
these changes were the result of the altered eosinophil/neutrophil 
balance or a more direct effect of the inhibitor remains to be 
determined. 
Treatment with demethyallosamidin did not result in neutrophil 
recruitment in allergic mice (Matsumoto, et al. 2009), whilst the effects 
of allosamidin and anti-AMCase sera on neutrophil cell number were not 
reported (Zhu, et al. 2004).  Bisdionin F-induced neutrophilia does 
correlate well with the inhibition of chitinase activity. Furthermore, in 
previous work the potential side effects of xanthine based (bisdionin) 
chitinase inhibitors were explored by monitoring phosphodiesterase 
inhibition, a known target of xanthine derivatives (Rao, et al. 2005).  
Results showed that as larger substituents were added to the N1 position 
of the xanthine structure, selectivity for the chitinases increased. 
Bisdionin F is further extended at this position, reducing the likelihood of 
off-target effects, although these cannot be fully excluded. Bisdionin F-
induced neutrophilia could be mediated, at least in part, through chitin 
accumulation in the lungs. Chitin has been shown to induce 
inflammatory cell recruitment (Reese, et al. 2007), including neutrophils 
(Da Silva, et al. 2008). Whilst these immunological actions of chitin 
would normally be limited in mammals by chitinase mediated chitin 
degradation, interference with chitinase enzymatic activity would likely 
result in chitin accumulation. Because bisdionin F exhibits selectivity for 
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AMCase, unlike allosamidin, which is more effective at inhibiting CHIT1 
(Boot, et al. 2001; Zheng, et al. 2005), the activity of CHIT1 in the lung 
should remain largely unaffected. Both CHIT1 and AMCase may be 
required to ensure full degradation and clearance of chitin. The level of 
chitinase activity in the lung and the predominance of one enzyme over 
the other may influence the size and quantity of chitin degradation 
products, which has been shown to determine the inflammatory outcome 
(Da Silva, et al. 2008). Importantly, if the ability of AMCase to break 
down chitin is important, the absence of neutrophils in PBS-challenged 
mice treated with bisdionin F suggests that other factors are at play and 
that an actively primed immune environment is required for chitin to 
induce neutrophilia. 
In addition to inhibiting chitinase activity (Matsumoto, et al. 2009; Zhu, 
et al. 2004), AMCase has been targeted by RNA interference (Yang, et al. 
2009) and anti-AMCase-sera (Zhu, et al. 2004). The overlap of all three 
treatments appears to be a reduction in eosinophilia, also observed with 
bisdionin F. Approaches that more specifically targeted AMCase, yielded 
additional effects not seen with broad chitinase inhibitors, including 
reduction of IL-13-induced chemotactic factors, antigen-specific IgE 
responses and airway hyper-responsiveness. Also consistent with our 
study, the RNA interference led to a small increase in neutrophils in 
animals infected with an adenoviral expressing short hairpin RNA (shRNA) 
against AMCase relative to mice which received a shRNA control (Yang, 
et al. 2009). Both anti-AMCase and shRNA treatment are likely to have 
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influenced protein levels and thus will not solely have addressed the role 
of AMCase enzymatic activity. 
These studies along with the findings presented here, emphasize the 
importance of generating specific tools for dissecting the role of 
chitinases during Th2-driven allergic inflammation. A recent study has 
developed high-throughput, fragment and virtual based screening 
methods to identify a selective inhibitor of AMCase activity (Cole, et al. 
2010). The study demonstrated inhibition of chitinase activity in vivo, 
albeit, at a much greater dosing regime (50 mg/kg twice daily) 
compared to bisdionin F but did not investigate the immunological or 
physiological consequences. We have used both structural and enzyme 
inhibition data to successfully design bisdionin F, and utilised this 
compound in vivo to selectively inhibit AMCase chitinolytic activity 
during allergic airway inflammation. Whilst our study has raised 
important questions regarding the therapeutic benefit of chitinase 
inhibition for the treatment of Th2-driven inflammatory conditions, 
bisdionin F is a valuable tool for understanding the yet unknown 
functions of AMCase. Further, studies in which the active site Asp138 
has been mutated to Ala have demonstrated distinct enzyme-dependent 
and -independent properties for AMCase which can both be blocked by 
allosamidin (Hartl, et al. 2009).  Thus, development of therapeutically 
useful inhibitors may still be possible, based on further refinement of 
the bisdionins in conjunction with a better understanding of both the 
chitinases and CLPs, some of which, like mutant AMCase, can still bind 
  

chitin (and thus presumably chitinase inhibitors) but cannot cleave it 
(Hartl, et al. 2009; Mohanty, et al. 2009). 
The active chitinases are highly conserved across mammals, while the 
CLPs represent more recent gene duplication events with subsequent 
loss-of-function mutations (Bussink, et al. 2007).  This has resulted in an 
intriguing situation in which all mammals express the highly conserved 
active enzymes chitotriosidase and AMCase but additionally express a 
broad range of diverse CLPs without known function. The data 
presented herein have already demonstrated novel inhibitory effects of 
AMCase on neutrophil recruitment potentially through MIP-1 signalling. 
Intriguingly, following the direct transfection of Ym1 (a murine CLP), 
into the lungs of naïve mice we have observed neutrophil recruitment 
and enhanced MIP-1 secretion (unpublished observations). Thus 
enhanced Ym1 expression following bisdionin F treatment (Fig. 6A) may 
explain the increases in MIP-1 and neutrophilia. This raises the exciting 
possibility that chitinases and CLPs have cross-regulatory properties.  
Further, the dissection of the differential roles of this expanded gene 
family may lead to future combination therapies in which both 
eosinophilia and neutrophilia can be repressed for the successful 
treatment of allergies. 
Although mouse CLPs cannot fully represent the human proteins, the 
evolutionary principles driving the remarkably rapid divergence of CLPs 
are likely to be shared across species. Thus studies in mice should allow 
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us to address fundamental functional differences between chitinases and 
CLPs. Indeed, the potential capacity of broad chitinase inhibitors such as 
allosamidin to bind a range of CLPs may have previously obscured 
AMCase-specific activities. It is only through the use of selective 
chemical tools like the bisdionins that we can begin to unravel the 
complex mechanistic and regulatory pathways of chitinase and CLP 
functions. 
  

SIGNIFICANCE – 
Chitotriosidase (CHIT1) and acidic mammalian chitinase (AMCase) are 
mammalian chitinases found in the lung and are upregulated during 
innate and adaptive immune responses, respectively. AMCase has 
previously been identified as a mediator in allergic inflammation and 
asthma, although most information regarding AMCase function has been 
provided through studies using allosamidin, a non-specific inhibitor of 
family 18 chitinases. To address the role of AMCase during Th2-driven 
inflammation, we used a rational approach to design a selective inhibitor 
of AMCase chitinase activity, bisdionin F. Bisdionin F showed in vivo 
efficacy in a murine model of allergic inflammation, and similar to 
allosamidin, attenuated lung chitinase activity, reduced eosinophil influx 
and improved ventilatory function. However, our studies with bisdionin 
F reveal new functions of AMCase that have previously gone unreported, 
likely due to the unspecific nature of other chitinase inhibitors. 
Neutrophils, whilst not typically associated with a Th2-allergic response, 
were strikingly enhanced with AMCase inhibition. While such results 
question the therapeutic potential of bisdionin F monotherapy and 
indeed other chitinase inhibitors for Th2-inflammatory conditions, it 
does not preclude the possibility to design AMCase inhibitors with 
appropriate actions. For example, beneficial effects of allosamidin and 
bisdionin F may be due to actions that are independent of direct 
chitinase activity. This same class of inhibitor could potentially be 
developed with activity against chitinase-like proteins (CLPs) without 
affecting chitinase activity. Thus, an understanding of the actions of the 
  

highly diverse CLP family, that are also upregulated during Th2-driven 
conditions, as well as enzyme-independent actions of AMCase, warrants 
urgent attention. Overall the approach of designing a specific class of 
inhibitor that shows selectivity for AMCase has provided an invaluable 
tool to begin dissecting the function of AMCase during pathology and has 
already alluded to the potential of cross-regulatory actions of the 
chitinase and CLP family members. 
  

EXPERIMENTAL PROCEDURES 
Bisdionin Synthesis 
Bisdionin C (Itahara and Imamura 1994), with an alkyl linker of three 
methylene units was synthesised as previously described (Schuttelkopf, 
et al. 2010). Bisdionin F was prepared according to the method of 
Allwood et al (Allwood, et al. 2007) by the alkylation of 1-(3­
bromopropyl)-3, 7-dimethyl-1H-purine-2,6(3H, 7H)-dione (Fischer, et al. 
1999) with 7-(4-methoxybenzyl)-3-methyl-1H-purine-2,6(3H, 7H)-dione 
(Sakai, et al. 1992), followed by removal of the 4-methoxybenzyl group 
under acidic conditions (Sakai, et al. 1992). Compounds were 
characterised by 1H and 13C NMR and HRMS and revealed no trace 
contamination by high molecular weight species such as LPS. Purity was 
>95% as judged by analytical HPLC. 
Protein expression, crystallisation and structure determination of 
hAMCase complexes. 
A fragment corresponding to hAMCase 22-398 (bp 64-1194) was ligated 
into the pPIC9 vector (Invitrogen) using the Xho I and Not I restriction 
sites. The enzyme was subsequently overexpressed as a secreted protein 
from the Pichia pastoris GS115 strain and purified using a combination of 
affinity chromatography and size-exclusion chromatography. Pure 
hAMCase was spin concentrated to 37 mg/ml in 25 mM HEPES pH 6.8, 250 
mM NaCl. The protein was crystallised at 30ºC from 75% saturated NaCl, 
0.1 M HEPES pH 7.4, using the hanging drop method. Crystals grew to an 
approximate size of 200 x 100 x 50 m. Crystals were cryo-protected in 
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50% saturated NaCl, 20% glycerol in 0.1 M HEPES pH 7.4 and subsequently 
flash frozen in liquid nitrogen. The binary complexes were formed by 
soaking crystals in reservoir solution containing saturated concentrations 
of bisdionin C (4 hrs) and bisdionin F (2 hrs) prior to cryo-protection. 
Data for hAMCase were collected at ID14-EH1 at the European 
Synchrotron Radiation Facilities (ESRF) using a cryo-stream of cold 
nitrogen (110 K). Processing and scaling were done using the HKL suite of 
programs (Otwinowski and Minor 1997). Initial phases were obtained by 
molecular replacement using MOLREP (Vagin and Teplyakov 1997) with 
the crystal structure of hCHIT1 as a search model (PDB entry 
1LG2;(Fusetti, et al. 2002)). Cross-validation (Kleywegt and Brunger 
1996) was applied by excluding 1% of the reflections throughout the 
refinement procedure. Rigid body and simulated annealing followed by 
several rounds of combined refinement (energy minimization and B-
factor refinement) using strict non-crystallographic symmetry were done 
using CNS (Brunger, et al. 1998). The graphical program O (Jones, et al. 
1991) combined with density modification including density averaging 
from the CCP4 program suite (Collaborative Computational Project 1994) 
was used for manual adjustments of the structures, and water molecules 
were included as oxygen atoms after each round of combined refinement 
using appropriate criteria. Refmac5 (Murshudov, et al. 1997) was used in 
latter stages of refinement. hAMCase crystallised in space group P212121, 
and the final models contain six monomers each consisting of 377 
residues per protein monomer. The overall fold of the six monomers are 
similar, with r.m.s.d values (C atoms) of 0.21 – 0.32 Å upon 
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superposition. In the interest of simplicity, the structures are discussed 
consistently using the first monomer in the coordinate files. Topologies 
for ligands were obtained using the PRODRG server(Schuttelkopf and van 
Aalten 2004) and ligands were included using unbiased Fo-Fc, calc 
electron density maps. 
Generation of AMCase expressing stable cell lines 
The full length-coding region of mAMCase was amplified using a lung 
cDNA template. The cDNA fragment was directionally cloned into 
pcDNA3.1 (Invitrogen), to generate a V5/His tagged plasmid.  TOP10 
competent cells were transformed with the AMCase plasmid and 
sequence confirmed. Mammalian COS-7 cells were transfected with 
AMCase-pcDNA3.1 plasmid using Lipofectamine 2000 (Invitrogen). COS-7 
cell supernatants were screened for AMCase protein by Western Blot and 
chitinase activity. A stable AMCase expressing cell line was generated 
using G418 selection medium (RPMI). 
Chitinase activity assay 
Chitinase activity of hAMCase, lung homogenates or AMCase COS-7 cell 
supernatants (serum-free) were determined using 4-methylumbelliferyl-
-D-N,N’,N”-triacetylchitotrioside and 4-methylumbelliferyl--D-N,N’,N”-
triacetylchitobioside as described. Samples were incubated with 
substrate (0.022 mM in 100 mM citric acid, 200 mM sodium phosphate 
buffer, pH 5.2) in a final volume of 50 μL. After a 10 min incubation at 
37°C, the reaction was stopped with the addition of 500 μL sodium 
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carbonate buffer (0.5 M sodium carbonate and 0.5 M and sodium 
bicarbonate pH 10.6). Liberated 4-methlyumberlliferone was quantified 
using a microplate fluorometer (excitation 360 nm/emission 440 nm). Ki 
and IC50 values were determined in the presence of different 
concentrations of inhibitor. Experiments were performed in duplicate or 
triplicate. 
OVA sensitization and challenge 
All experiments used female BALB/c mice, 6-8 weeks old. Mice were 
kept in individually ventilated cages and all experiments were conducted 
under UK Home Office guidelines. Mice were sensitized (day 0) and 
boosted (day 14) i.p. with 20 μg OVA (Grade V, Sigma) adsorbed to 9% 
potassium alum. Mice were either challenged on day 28 and 30 with 50 
μg OVA or PBS by the intratracheal route, or were challenged with 1% 
OVA or PBS by aerosol for 30 min on day 28 to day 30. Bisdionin F or 
vehicle (2% DMSO in PBS) was administered i.p., 2hrs prior to each 
challenge at doses indicated in the text. Necropsies were performed 24 
hrs after the final airway challenge. 
Ventilatory Function 
On day 30, prior to the final OVA challenge and bisdionin F dose, 
ventilatory function (enhanced pause (penH)) was measured using 
unrestrained whole-body plethysmography (Buxco Systems) and analyzed 
with system XA software (Buxco Electronics) as previously described 
(Hamelmann, et al. 1997).  Briefly, Conscious mice were placed in 
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individual chambers for a 10 min acclimatisation period. Spontaneous 
breathing patterns in mice relate to changes in chamber air pressure, 
which are measured by a transducer attached to the chamber wall. 
Differences in the rates of pressure change during peak inspiration and 
peak expiration and the timing of expiration are used to calculate penH 
according to the following equation; penH = ((expiratory time/relaxation 
time) – 1) x (peak expiratory flow (mL/s)/peak inspiratory flow (ml/s)).  
PenH measurements are not used as a quantitative measurement that 
relates to airway size and rather reflect changes to ventilation following 
bronchoconstriction. Baseline measurements of penH were made 
following an aerosol of PBS. Doubling doses of methacholine (3.12550 
mg/mL in PBS, Sigma) were aerosolized for 2 min followed by 5 min data 
collection. PenH measurements were averaged for the entire dose 
period. 
Bronchoalveolar Lavage 
Approximately 24 hrs after the last challenge, mice were killed, the 
trachea cannulated and internal airspaces lavaged with 400 μL of 0.25% 
BSA in PBS followed by three 300 μL washes. Total cell numbers were 
counted and cytospins prepared for differential cell counts which were 
assessed by morphology following Diff Quick staining (Reagena). BALF 
was centrifuged at 1200 g and supernatant stored at -20°C for further 
analysis. 
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Lung protein homogenates 
Protein from dissected lung was homogenised (TissueLyser, Qiagen) in 
lysis buffer containing protease cocktail inhibitor (Sigma). Samples were 
incubated for 20 min on ice, prior to centrifugation 10,000 g to removed 
cell debris. Protein amounts were quantified with Coomassie (Bradford) 
Reagent. Homogenates were stored at -70°C for use in the chitinase 
activity assay. 
Histology 
Following BAL, the right lobe of the lung was fix-perfused with 4% 
formaldehyde and subsequently processed to paraffin and embedded. 
Standard H&E staining was performed to gross pathology and lung 
neutrophils were visualised by naphthol AS-D choloracetate esterase 
staining (Sigma). 
RNA extraction and quantitative real-time PCR 
One part of the left lobe of the lung, removed following BALF, was 
stored in RNAlater (Ambion) at 4°C for up to 4 weeks. Lung samples 
were homogenized in RLT lysis buffer using TissueLyser (Qiagen) and 
total RNA extracted using RNeasy mini spin columns (Qiagen). 1 μg of 
RNA was used for synthesis of cDNA using Moloney murine leukemia virus 
reverse transcriptase. Relative quantification of genes was carried out 
by RT-PCR using the Roche Lightcycler, as previously described (Nair, et 
al. 2005). PCR amplication was analysed using 2nd derivative Maximum 
alogarithm (LightCycler 480 SW 1.5, Roche) and the expression of the 
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gene of interest was normalised to the housekeeping gene, GAPDH. 
Primer sequences used were as follows: GAPDH- For 
ATGACATCAAGAAGGTGGTG, Rev CATACCAGGAAATGAGCTTG; Ym1- For 
TCACAGGTCTGGCAATTCTTCTG, Rev TTGTCCTTAGGAGGGCTTCCTC; Pro 
Collagen I- For – AACTGGACTGTCCCAACCCC, Rev 
TCCCTCGACTCCTACATCTTCTG; CCL3- For TGCCCTTGCTGTTCTTCTCT, 
Rev GTGGAATCTTCCGGCTGTAG; MMP-12- For 
CAATTGGAATATGACCCCCTGT, Rev AGCAAGCACCCTTCACTACAT; and 
TIMP-1- For GTGGGAAATGCCGCAGAT, Rev GGGCATATCCACAGAGGCTTT. 
Cytokine and chemokine secretion from draining lymph node cell 
cultures 
The draining thoracic lymph nodes (tLN) were dissected and single cell 
suspensions made before being plated out at 1x106 cells/mL in 96-well 
plates (RPMI 1640 supplemented with L-glutamine, penicillin 
streptomycin and FCS). Cells were stimulated with 500 μg/mL OVA and 
incubated for 72 hrs at 37°C, 5% CO2. MIP-1 levels were measured in 
cell-free supernatants using a Luminex kit (Invitrogen) and samples were 
read with a Luminex 100 multiplex bead array system. 
Statistical analysis 
Data are expressed as the mean ± standard error of the mean, with 
individual numbers indicated for each experiment. Statistical analysis 
was performed with PRISM 4.0 (Graphpad Software). Differences 
  

between groups were determined using a one-way ANOVA with Dunnetts 
post-hoc test. A P<0.05 was considered a significant difference. 
  
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Figure Legends 
Figure 1:  (A) Chemical structures and atom numbering of bisdionin C 
and bisdionin F are shown with the differing methyl/hydrogen moieties 
highlighted in red. (B) Lineweaver-Burk plot showing bisdionin F 
inhibition of hAMCase at different concentrations. The data are 
compatible with a competitive inhibition model, giving a Ki of 420 ± 10 
nM. (C) Stereo figures of the active sites (monomer A) of the hAMCase­
bisdionin C (top) and hAMCase-bisdionin F (bottom) complexes. Unbiased 
Fo-Fc c electron density maps are contoured at 2.5. Protein side 
chains, glycerol and ligand molecules are shown as a stick models with 
grey, yellow and magenta C atoms, respectively. hAMCase residues not 
conserved compared to CHIT1 are shown with orange C atoms. Water 
molecules interacting with the ligand are shown as orange spheres and 
hydrogen-bonding interactions are shown as dotted green lines. The 
second, less defined, ligand molecules stacking against Trp99 and Trp218 
are omitted for clarity. N-acetyl glucosamine residues taken from the 
HCGP-39 in complex with chitin (PDB ID 1HJW) and Asp138 in the “up­
conformation” are shown as stick models with transparent green C 
atoms. 
 
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Figure 2: (A) IC50 values (Ki values are shown in parenthesis) of bisdionin 
C and F compounds against hAMCase and hCHIT1. All values are given in 
M. (B) Bisdionin F inhibits recombinant mAMCase enzymatic activity in 
vitro. Chitinase activity was determined using a fluorescent 4­
methylumbelliferyl (4-MU) substrate. An AMCase expressing COS-7 cell-
free supernatant was used as a source of enzymatically active 
recombinant mAMCase. rAMCase, in the presence of 4-MU substrate, 
was incubated with DMSO vehicle or increasing concentrations of 
bisdionin F for 10 min at 37°C. Chitinase activity is measured relative to 
the amount of substrate hydrolysed/hr/mL sample. IC50= 2.21 ± 0.18 μM. 
 
 
Figure 3: Inhibition of allergen-induced lung chitinase activity and 
changes to cell recruitment in lavage and lung tissue. (A) Chitinase 
activity measured in lung homogenates from PBS/OVA-challenged mice 
treated with vehicle or bisdionin F. Bisdionin F reduced chitinase activity 
(expressed as 4MU substrate hydrolysed/hour/mg of lung tissue) in both 
PBS-challenged and OVA-challenged mice. (B) Total cell number and (C) 
differential cell counts, of macrophages, lymphocytes, neutrophils and 
eosinophils in bronchoalveolar lavage from bisdionin F and vehicle 
treated PBS and OVA –challenged mice. (D) Representative H&E stained 
lung sections (i) Vehicle PBS-challenged mice, (ii) bisdionin F PBS-
challenged mice, (iii) vehicle OVA-challenged mice and (iv) bisdionin F 
OVA-challenged mice. Magnification x400. (E) Representative H&E 
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stained lung sections from a second independent experiment; (i) vehicle 
OVA-challenged mice and (ii) bisdionin F OVA-challenged mice. 
Magnification x200. (F) Representative lung sections stained with 
naphthol AS-D choloracetate esterase showing (i) vehicle OVA-challenged 
mice or (ii) bisdionin F OVA-challenged mice. Neutrophils exhibit red 
staining, cell nuclei stained with haematoxylin. Magnification x400. (G) 
Protein levels of MIP-1 in supernatant of tLN cells from PBS or OVA -
challenged mice, cultured in RPMI or OVA antigen (0.5 mg/mL) for 72 
hrs. (H) Expression of MIP-1 mRNA from lung of PBS and OVA – 
challenged mice, normalised to the level of housekeeping gene, GAPH, 
in individual lung samples. Chitinase inhibitor, bisdionin F, 5 mg/kg i.p., 
n=5-7 per group. NS, not significant, * P<0.05, **P<0.01 and ***P<0.001 
compared to vehicle PBS; #P<0.01, ##P<0.01, ###P<0.001. Data is 
representative of 3 individual experiments. 
Figure 4: Treatment with two different doses of bisdionin F during 
allergic inflammation. (A) Eosinophil and neutrophil cell numbers in the 
bronchoalveolar lavage from chitinase inhibitor treated allergic mice 
compared to vehicle treatment. (B) Chitinase activity, measured in lung 
homogenates from OVA-challenged mice treated. (C) Relationship of 
chitinase inhibition on ventilatory function in allergic animals. PenH 
values were measured in conscious, unrestrained mice administered with 
increasing doses of aerosolised bronchoconstrictor, methacholine. 
Vehicle-treated PBS-challenged mice, open squares; Vehicle-treated 
OVA-challenged mice, closed squares; 1 mg/kg bisdionin F OVA-
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challenged, open circles; 5 mg/kg bisdionin F closed circles, dashed line. 
Chitinase inhibitor, bisdionin F 1 and 5 mg/kg, i.p.; n=5-6 mice per 
group. NS not significant, **P<0.01 and ***P<0.001 compared to vehicle 
PBS and #P<0.05 and ##P<0.01 compared to vehicle OVA-challenged 
mice. 
Figure 5: Chitinase inhibition alters the expression of genes involved 
implicated in lung tissue remodelling. mRNA expression of (A) Ym1, (B) 
pro-collagen I, (C) TIMP-1 and (D) MMP-12 were measured in RNA 
extracted from lung tissue of PBS-challenged animals or vehicle and 
bisdionin F -treated allergic animals. (E) The ratio of MMP-12:TIMP-1 
mRNA expression. Chitinase inhibitor, bisdionin F, 1 and 5 mg/kg i.p.; 
n=5-6 mice per group. *P<0.05, **P<0.01, ***P<0.001 compared to vehicle 
PBS-challenged mice; #P<0.05 and ###P<0.001 compared to vehicle OVA-
challenged mice. 
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Table 1: Summary of data collection and structure refinement statistics 
for the hAMCase-bisdionin C and F complexes. Values for the highest 
resolution shell are shown in parenthesis. 
hAMCase + bisdionin C hAMCase + bisdionin F 
Resolution (Å) 20-2.20 (2.25-2.20) 20-2.25 (2.33-2.25) 
Cell dimensions (Å) 145.21 149.07 152.08 144.78 149.19 151.28 
Number of unique 
reflections 
161985 154470 
Multiplicity 4.3 4.1 
Rmerge (%) 10.1 (69.6) 9.6 (57.7) 
I/(I) 14.1 (2.7) 14.8 (2.7) 
Completeness (%) 99.9 (99.9) 99.6 (99.8) 
Number of atoms in 
refinement 
19339 19347 
Number of solvent 
molecules 
1057 1119 
Rwork (%) 18.1 17.3 
Rfree (%) 22.8 21.9 
Average protein B-factor 
(Å2) 
31.3 28.5 
Average ligand B-factor 
(Å2) *1 
42.0 22.6 
Average solvent B-
factor (Å2) 
31.5 29.7 
r.m.s.d. bond lengths (Å) 0.022 0.023 
r.m.s.d. bond angels (º) 1.86 1.89 
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Ramachandran plot 
statistics (%) 
Residues in favoured 
regions 
97.7 98.0 
Residues in allowed 
regions 
2.1 2.0 
Residues in outlier 
regions 
0.1 0.0 
*1  calculated from ligand molecules occupying the -1 and -3 subsites. 
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